A-Alpha Bio Funding & Investors
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions. Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications. A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
aalphabio.comTotal Amount Raised: $49,551,472
A-Alpha Bio Funding Rounds
Series A
$22,400,000
Series A Investors
Perceptive AdvisorsMadrona Venture GroupBreakout VenturesFarvatn VentureGrant
$670,472
Grant Investors
National Science Foundation (NSF)Grant
$2,400,000
Grant Investors
Oxford Construction of PennsylvaniaSeries A
$20,000,000
Series A Investors
Madrona Venture GroupLux CapitalPerceptive AdvisorsSeed
$2,800,000
Seed Investors
OS FundAME Cloud VenturesBOOM Capital.Washington Research FoundationSahsen VenturesMadrona Venture GroupGrant
$256,000
Grant Investors
National Science Foundation (NSF)Grant
$800,000
Grant Investors
Bill & Melinda Gates FoundationGrant
$225,000
Grant Investors
National Science Foundation (NSF)